{"nctId":"NCT01810783","briefTitle":"Brexpiprazole in Patients With Schizophrenia","startDateStruct":{"date":"2013-07"},"conditions":["Schizophrenia"],"count":210,"armGroups":[{"label":"Brexpiprazole","type":"EXPERIMENTAL","interventionNames":["Drug: Brexpiprazole"]}],"interventions":[{"name":"Brexpiprazole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient has completed the lead-in study 14644A.\n* The patient is judged to potentially benefit from 52-week treatment with brexpiprazole according to the clinical opinion of the investigator.\n* The patient agrees to protocol-defined use of effective contraception.\n\nExclusion Criteria:\n\n* The patient has been diagnosed with a primary psychiatric disorder other than schizophrenia during Study 14644A.\n* The patient has a clinically significant unstable illness diagnosed during Study 14644A.\n* The patient, in the opinion of the investigator or according to Columbia-Suicide Severity Rating Scale (C-SSRS), is at significant risk of suicide.\n* The patient has an abnormal ECG or other abnormal ECG tests that are, in the investigator's opinion, clinically significant.\n* The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.\n\nOther inclusion and exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety and Tolerability","description":"Number of treatment-emergent adverse events (TEAEs)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"337","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":31,"n":209},"commonTop":["Weight increased","Headache","Insomnia"]}}}